At present, Lupus Nephritis (LN) is still awaiting a biomarker to better monitor disease activity, guide clinical treatment, and predict a patient’s long-term outcome. In the last decade, novel biomarkers have been identified to monitor the disease, but none have been incorporated into clinical practice. The transmembrane receptor neuropilin-1 (NRP-1) is highly expressed by mesangial cells and its genetic deletion results in proteinuric disease and glomerulosclerosis. NRP-1 is increased in kidney biopsies of LN. In this work we were interested in determining whether urinary NRP-1 levels could be a biomarker of clinical response in LN. Our results show that patients with active LN have increased levels of urinary NRP-1. When patients were divided according to clinical response, responders displayed higher urinary and tissue NRP-1 levels at the time of renal biopsy. Areas under the receiver operating characteristic curve, comparing baseline creatinine, proteinuria, urinary NRP-1, and VEGFA protein levels, showed NRP-1 to be an independent predictor for clinical response. In addition, in vitro studies suggest that NRP-1could promote renal recovery through endothelial proliferation and migration, mesangial migration and local T cell cytotoxicity. Based on these results, NRP-1 may be used as an early prognostic biomarker in LN.
Neuropilin-1; Lupus nephritis; Urinary biomarker
Torres-Salido MT, Sanchis M, Solé C, Moliné T, Vidal M, Vidal X, et al. Urinary neuropilin-1: a predictive biomarker for renal outcome in lupus nephritis. Int J Mol Sci. 2019 Sep 17;20(18):4601.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/5066
This item appears in following collections
- HVH - Articles científics 
The following license files are associated with this item: